Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Thomas Guerrero-Garcia"'
Autor:
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, Efstathios Kastritis, Shirley D’Sa, Ramon Garcia-Sanz, Cécile Tomowiak, Bénédicte Hivert, Elise Toussaint, Caroline Protin, Jithma P. Abeykoon, Thomas Guerrero-Garcia, Gilad Itchaki, Josephine M. Vos, Anne-Sophie Michallet, Sophie Godet, Jehan Dupuis, Stéphane Leprêtre, Joshua Bomsztyk, Pierre Morel, Véronique Leblond, Steven P. Treon, Meletios A. Dimopoulos, Prashant Kapoor, Alain Delmer, Jorge J. Castillo
Publikováno v:
Haematologica, Vol 106, Iss 11 (2020)
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) and is usually associated with a poor prognosis. The objective of this study was to develop and validate a prog
Externí odkaz:
https://doaj.org/article/0931a2c3a1de4a5db0e8afca81e892d7
Autor:
Peter O'Gorman, Jacob P. Laubach, Michael E. O'Dwyer, Janusz Krawczyk, Andrew J. Yee, Oonagh Gilligan, Mary R. Cahill, Jacalyn Rosenblatt, John Quinn, Philip T. Murphy, Heidi DiPietro, Meegahage Ratnakanthi Perera, Gerard M. Crotty, Kristen Cummings, Patrick J. Hayden, Paul Browne, Alexandra Savell, Hilary M. O'Leary, Denis O'Keeffe, Kelly Masone, Brian J. Hennessy, Thomas Guerrero Garcia, Kathleen Scott, Khalid Saeed, Giada Bianchi, Paul Dowling, Ciara Tierney, Paul G. Richardson
Publikováno v:
American journal of hematologyREFERENCES. 97(5)
There are limited prospective data on lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVd) in transplant-eligible/transplant-ineligible patients with newly diagnosed multiple myeloma. Reliable biomarkers for efficacy and toxicity are requ
Autor:
Dharminder Chauhan, Constantine S. Mitsiades, Thomas Guerrero-Garcia, Teru Hideshima, Jacob P. Laubach, Kenneth C. Anderson, Sara Gandolfi, Paul G. Richardson
Publikováno v:
Expert Review of Proteomics. 15:1033-1052
INTRODUCTION Proteasome inhibitors (PIs) are therapeutic backbones of multiple myeloma treatment, with PI-based therapies being standards of care throughout the treatment algorithm. Proteasome inhibition affects multiple critical signaling pathways i
Autor:
Alec Petersen, Ursula A. Matulonis, Prabhsimranjot Singh, Paul G. Richardson, Robert Stuver, Thomas Guerrero-Garcia
Publikováno v:
Case Reports in Hematology, Vol 2018 (2018)
Case Reports in Hematology
Case Reports in Hematology
Multiple myeloma is the most common plasma cell dyscrasia and causes 2% of all cancer deaths in Western countries. Ovarian carcinosarcomas are very rare gynecological malignancies and account for only 1–2% of all ovarian tumors. In this case, we re
Autor:
Thomas Guerrero-Garcia, Steven P. Treon, Shirley D'Sa, Lukshe Kanagaratnam, Joshua Bomsztyk, Jorge J. Castillo, Gilad Itchaki, Veronique Leblond, Cécile Tomowiak, Josephine M.I. Vos, E. Toussaint, Sophie Godet, Bénédicte Hivert, Pierre Morel, Anne Sophie Michallet, Eric Durot, Alain Delmer
Publikováno v:
Hematological Oncology. 37:401-403
Publikováno v:
Leukemia Research. 62:12-16
Plasmablastic lymphoma (PBL) is a rare and hard to treat disease. With current standard chemotherapeutic regimens, PBL is associated with a median overall survival of 12-15 months. We performed a systematic review of the literature through March 31,
Publikováno v:
Novel Therapeutics for Rare Lymphomas ISBN: 9783030256098
Plasmablastic lymphoma (PBL) and primary effusion lymphoma (PEL) are rare CD20-negative variants of diffuse large B-cell lymphoma. Both conditions were initially described in patients with underlying HIV infection, but cases of PBL and PEL have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a29a5aeb35113b38e9aebbaf21cdf9b
https://doi.org/10.1007/978-3-030-25610-4_7
https://doi.org/10.1007/978-3-030-25610-4_7
Autor:
Meral Beksac, Waldemar Sawicki, Roman Hájek, Jorge J. Castillo, Anna Waszczuk-Gajda, Dorotea Fantl, Lidia Usnarska-Zubkiewicz, Irit Avivi, Jacob P. Laubach, Grzegorz Charliński, Vania Hungria, Michel Delforge, Giuseppe Mele, Ravi Vij, Krzysztof Mądry, Alessandro Gozzetti, Vibor Milunovic, Paul G. Richardson, Jieqi Liu, Edvan de Queiroz Crusoe, Agoston Gyula Szabo, Iwona Hus, Anders Waage, David H. Vesole, Agnieszka Kopacz, Artur Jurczyszyn, Julio Dávila, David Jayabalan, Mark A. Fiala, Jacek Czepiel, Jakub Dębski, Erden Atilla, Norbert Grząśko, Thomas Guerrero-Garcia
Publikováno v:
Jurczyszyn, A, Castillo, J J, Avivi, I, Czepiel, J, Davila, J, Vij, R, Fiala, M A, Gozzetti, A, Grząśko, N, Milunovic, V, Hus, I, Mądry, K, Waszczuk-Gajda, A, Usnarska-Zubkiewicz, L, Dębski, J, Atilla, E, Beksac, M, Mele, G, Sawicki, W, Jayabalan, D, Charliński, G, Gyula Szabo, A, Hajek, R, Delforge, M, Kopacz, A, Fantl, D, Waage, A, Crusoe, E, Hungria, V, Richardson, P, Laubach, J, Guerrero-Garcia, T, Liu, J & Vesole, D H 2019, ' Secondary plasma cell leukemia : a multicenter retrospective study of 101 patients ', Leukemia and Lymphoma, vol. 60, no. 1, pp. 118-123 . https://doi.org/10.1080/10428194.2018.1473574
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a3a648a5b6a94ec452aeb9c9e1d82f
https://ruj.uj.edu.pl/xmlui/handle/item/95218
https://ruj.uj.edu.pl/xmlui/handle/item/95218
Autor:
Michael Gilbertson, Daan Dierickx, Adam J. Olszewski, George Grigoriadis, Thomas Tousseyn, Michele Bibas, Jorge J. Castillo, Emmanuelle Tchernonog, Guillaume Cartron, Yevgeny Linnik, Thomas Guerrero-Garcia, John L. Reagan, Frederick Lansigan, Pasquale L. Fedele, Renzo Mogollon, José-Tomás Navarro, Francesco Baldini, Slavisa Ninkovic, Kate Cwynarski
Publikováno v:
British Journal of Haematology
British Journal of Haematology, Wiley, 2018, 〈10.1111/bjh.15156〉
Repositorio Académico USMP
Universidad San Martín de Porres-USMP
USMP-Institucional
Universidad de San Martín de Porres
instacron:USMP
British Journal of Haematology, Wiley, 2018, 〈10.1111/bjh.15156〉
Repositorio Académico USMP
Universidad San Martín de Porres-USMP
USMP-Institucional
Universidad de San Martín de Porres
instacron:USMP
Plasmablastic lymphoma (PBL) is a rare and aggressive CD20‐negative lymphoma associated with poor outcomes. Multiple studies have shown median survival times of 12–18 months (Castillo et al, 2012; Schommers et al, 2013; Morscio et al, 2014). Seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f93ffa047e3e34ac25117cd90908ac56
https://hal.archives-ouvertes.fr/hal-01816005
https://hal.archives-ouvertes.fr/hal-01816005
Autor:
David Jayabalan, Dorotea Fantl, Renata Guzicka-Kazimierczak, Grzegorz Charliński, Wanda Knopinska-Posluszny, Agnieszka Druzd-Sitek, Mark A. Fiala, Agnieszka Kopacz, Agnieszka Barchnicka, Jakub Radocha, Waldemar Sawicki, Norbert Grząśko, Roman Hájek, Iwona Hus, Michel Delforge, Anders Waage, Alessandro Gozzetti, Jorge J. Castillo, Xavier Leleu, Artur Jurczyszyn, Irit Avivi, Andrew Yee, Thomas Guerrero-Garcia, David H. Vesole, Erden Atilla, Julio Dávila, Jieqi Liu, Pawel Robak, Marek Rodzaj, Giuseppe Mele, Valentine Richez, Agoston Gyula Szabo, Anna Waszczuk-Gajda, Anna Masternak
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d25c451bcce56168d21ec5846028f3
https://ruj.uj.edu.pl/xmlui/handle/item/142394
https://ruj.uj.edu.pl/xmlui/handle/item/142394